Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Place of General Medical During Oncology Care Management (MGPEC_Onco)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03416465
Recruitment Status : Recruiting
First Posted : January 31, 2018
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
Institut de Cancérologie de Lorraine

Tracking Information
First Submitted Date January 24, 2018
First Posted Date January 31, 2018
Last Update Posted Date June 6, 2019
Actual Study Start Date May 16, 2018
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: January 24, 2018)
Patients in unscheduled hospitalization [ Time Frame: 1 day ]
Percentage of patients in unscheduled hospitalization who have seen their general practitioner
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Place of General Medical During Oncology Care Management
Official Title Place of General Medical During Oncology Care Management
Brief Summary

The Purpose of MGPEC_ONCO is to see if patient consult their general practitioner during the management of their cancer, especially before hospitalization. The study concerns not planned hospitalizations in medicine service.

Before leaving hospital, the patient completes the survey, other data are taken in patient record

Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Any patient hospitalized in a medical service in an unscheduled way
Condition Oncologic Disorders
Intervention Behavioral: medical questionnaire
The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: January 24, 2018)
300
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2020
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patient undergoing oncology treatment or ≤ 1 year of the latest oncology treatments
  • Patient hospitalized in a medical service in an unscheduled way
  • Age > or = 18 years old
  • Patient informed and not opposed to the study
  • Patient able and agreeing to follow all study procédures
  • Patient must be affiliated to a social security system

Exclusion Criteria:

  • Patient hospitalized in surgery and continuing care services
  • Patient deprived of liberty or under supervision
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: MERLIN JEAN LOUIS +33 3 83 59 83 07 jl.merlin@nancy.unicancer.fr
Contact: FERNANDES LAURINDA +33 3 83 59 84 87 l.fernandes@nancy.unicancer.fr
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT03416465
Other Study ID Numbers 2017-A03429-44
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Institut de Cancérologie de Lorraine
Study Sponsor Institut de Cancérologie de Lorraine
Collaborators Not Provided
Investigators
Principal Investigator: HENRY ALINE Institut de Cancérologie de Lorraine
PRS Account Institut de Cancérologie de Lorraine
Verification Date June 2019